

On page 2, please replace paragraph [001] with the following:

Q2 --[001] This application is a continuation-in-part of U.S. Patent Application No. 09/655,728, filed September 5, 2000, now U.S. Patent No. 6,492,164, which was a division of U.S. Patent Application No. 08/894,511, filed August 19, 1997, now U.S. Patent No. 6,143,530, which was the national stage application of PCT/FR96/00274 (not published in English), filed February 21, 1996, all of which are incorporated by reference herein.--

**IN THE CLAIMS:**

Please cancel claims 1-3, 5-8, 17, 19-22, 29, 30, and 34-37 without disclaimer of or prejudice to the subject matter recited therein. Please amend claims 4, 12, 13, 24, 26, and 43 as follows:

Q3 4. The molecule according to claim 57, wherein said molecule is MC3909, MC3948, or MC4009.

Q4 12. The molecule according to claim 13, wherein said molecule is MC3955 or MC4007.  
13. The molecule according to claim 10, wherein the sequence that forms a triple helix and the sequence attB are contiguous and are as set forth in SEQ ID NO: 13.

Q5 24. The plasmid according to claim 23, further comprising an origin of replication and a selection marker gene, wherein the origin of replication and selection marker gene are located outside said expression cassette.

Q6 26. The plasmid according to claim 24, wherein the selection marker gene is a gene for kanamycin resistance or the tRNA suppressor supPhe.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

43. The method according to claim 42, wherein the cultured host cell is brought into contact with the integrase and the excisionase by transforming or infecting the cultured host cell with a plasmid or a phage containing a gene for at least one of the recombinase or the excisionase.

Please add claim 57, as follows:

~~53~~ 57. A double-stranded DNA molecule, comprising an expression cassette containing a gene of interest under control of a transcription promoter and a transcription terminator active in a mammalian cell, wherein said molecule:

- is in circular and supercoiled form,
- lacks an origin of replication,
- lacks a marker gene, and
- comprises a sequence *attL* resulting from site-specific recombination between an *attB* sequence and an *attP* sequence or between an *attB* derived sequence and an *attP* derived sequence, said region being located outside the expression cassette;
- wherein said molecule further comprises a sequence that interacts specifically with an oligonucleotide to form a triple helix by hybridization; and
- wherein the sequence that forms a triple helix and the sequence *attL* are contiguous and are as set forth in SEQ ID NO: 12.

#### REMARKS

With entry of this Amendment, claims 4, 9-16, 18, 23-28, 31-33, and 38-57 are pending in this application. Applicants have cancelled claims 1-3, 5-8, 17, 19-22, 29, 30, and 34-37 without disclaimer of or prejudice to the subject matter recited therein.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com